At follow-up, unadjusted analyses showed lower HbA1c in the GLP-1RA group (36 vs 44 mmol/mol, p = 0.03), but adjusted models revealed no statistically significant monthly HbA1c change ( 1.1, p = 0.308)
GLP-1RAs appear to offer a potential dual therapeutic advantage, simultaneously targeting metabolic dysfunction and immune-mediated inflammation, thereby representing a potentially promising strategy in the management of early-stage PsA early PsA, although robust clinical evidence in this setting is currently lacking
Regular Monitoring and Progress Assessment: Weekly or bi-weekly appointments track weight loss, medication tolerance, and overall health markers
The connection between blood sugar and liver health runs deep
* Monitor your body composition, not just scale weight